Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for Value Assessment
8 April 2019
A new OHE Research Paper reviews a recent report on cancer pricing published by the World Health Organization. The authors argue that the report fails to…
Can Transparency Lower Prices and Improve Access to Pharmaceuticals? Five Questions We Think Matter a Lot
29 March 2019
Transparency as a principle of good governance is not the same as transparency for improving access by lowering prices. In fact, the former often carries an…
Can Transparency Lower Prices and Improve Access to Pharmaceuticals? Not So Fast…
28 March 2019
Report does not recommend price transparency for on-patent medicines, but buyers should share multi-source product price data among themselves. Transparency of the procurement process encourages bidders.…
Is Rate Of Return Pricing A Useful Approach When Value-Based Pricing Is Not Appropriate?
22 March 2019
Value-based pricing (VBP) is an efficient method for pricing new drugs. Rate of return pricing could, however, be useful in two cases: treatments for ultra-rare diseases,…
Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England
20 March 2019
Estimating a cost-effectiveness threshold reflecting the opportunity cost of adopting a new technology in a health system is not easy. A new OHE report provides empirical…
HTA in Japan: Failing to Meet International Good Practice?
15 March 2019
The Japanese government has recently announced new plans to implement HTA from April 2019. The ISPOR HTA Task Force published ‘Good Practices in HTA’ in January…
Abolishing Pharmaceutical Rebates in the US? Looking at the Trade-Offs
12 March 2019
The combination of rising drug costs in the US and increasing financial stress for individual patients has triggered intense national concern. One target has come under…
The World Needs Better Drugs for TB. The Center for Global Development and OHE Have a Proposal and We Need your Feedback
5 March 2019
Innovation is a critical tool in the global fight against tuberculosis (TB), an infectious disease that primarily affects the poor and vulnerable and ranks among the…
Pricing and Paying for Cures: Early Experience with HTA of Gene Therapy in the USA
28 February 2019
In this OHE Seminar Briefing, Dr Steven Pearson, President of ICER, sets out ICER’s early experiences of using HTA to assess gene therapy in the US,…